# Twelve Questions. No Hype.

> FAQ — Recovery & Tissue Repair Research Peptides — Answers to common questions about Recovery & Tissue Repair research peptides BPC-157, TB-500, and KPV, with evidence limits and citations.

**FIELD QUESTIONS / DIRECT ANSWERS**

Short answers anchored to the signed literature corpus.

## What does BPC-157 do in the body?

Human effects are not established. In cell and animal models, BPC-157 influences VEGFR2-linked blood-vessel signaling, nitric oxide, cell movement, and tissue-protection pathways [4][5]. A two-person human pilot only assessed limited safety observations [1]. It did not test healing efficacy.

## Is BPC-157 a growth hormone?

No. BPC-157 is a fifteen-amino-acid peptide derived from a gastric protein sequence. It is not growth hormone. Preclinical research has linked it with growth-hormone-receptor signaling in tendon cells, but interacting with that pathway does not make the compound a hormone or establish a human growth effect.

## Does BPC-157 work immediately?

The clinical literature cannot answer that question. Human efficacy trials are lacking [2]. Animal pharmacokinetic work found rapid breakdown and a half-life below thirty minutes, but drug presence and repair effect are different measures [3]. Community timelines are anecdotal, not clinical evidence.

## Does BPC-157 damage the liver?

No reliable human risk estimate exists. A pilot in two healthy adults found no measurable liver-marker change under its conditions [1]. That sample is far too small to rule out uncommon, delayed, interaction-related, or product-related harm. The broader human safety profile remains unknown [2].

## What is TB-500?

TB-500 is Ac-LKKTETQ, a synthetic seven-amino-acid fragment of thymosin beta-4. It contains an actin-binding motif. Most published repair research used full-length thymosin beta-4, not the TB-500 fragment [8][10]. The distinction is central.

## What does TB-500 stand for and what does TB stand for in TB-500?

The name refers to a thymosin beta-4-related research fragment. In commercial and anti-doping contexts, TB-500 generally denotes the acetylated LKKTETQ heptapeptide. It should not be treated as another name for the full forty-three-amino-acid parent protein.

## What is TB-500 used for in research?

It is discussed in relation to cell movement, angiogenesis, wound repair, and musculoskeletal recovery. The direct fragment evidence is limited. Reviews of repair mechanisms and experimental outcomes largely concern full-length thymosin beta-4 [6][8]. TB-500 has no approved therapeutic use.

## Does TB-500 work for muscle tears and recovery from exercise?

Controlled human evidence for the fragment is absent. Research-use communities report recovery and mobility changes, but that is anecdotal, not clinical evidence. The corpus review finds animal promise across unapproved peptides while emphasizing scarce human safety data and potential harm [6].

## What is KPV peptide?

KPV is the tripeptide lysine-proline-valine. It is the final three-amino-acid sequence of alpha-MSH. Research describes it as retaining anti-inflammatory activity without the pigment-forming action of the full hormone [15]. It is not an approved medicine.

## What does KPV peptide do?

In experimental systems, KPV enters intestinal epithelial cells through PepT1 and suppresses NF-kB and MAP-kinase inflammatory signaling [13]. Other work points to an interleukin-1 beta-related route [17]. These are cell and animal findings, not demonstrated human effects.

## What is KPV peptide used for?

Researchers have studied KPV in mouse colitis, intestinal-cell inflammation, targeted gut-delivery systems, and rabbit corneal wound repair [11][12][13][14][16]. Those are research uses. No validated human therapeutic use appears in the signed corpus.

## What is KPV peptide good for?

The evidence supports a preclinical question, not a human-use conclusion. KPV is a focused candidate for studying inflammatory control and mucosal or epithelial repair. Its transporter route and animal results are coherent [13][16]. Human efficacy, safety, delivery, and exposure remain untested.

---

An independent ascent map for repair evidence; no storefront, clinical direction, or borrowed certainty.